Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
Journal of Hepatocellular Carcinoma · 2023-09 · Volume 10 · 1435-1443
DOI: 10.2147/jhc.s423684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2023-09. Verfasst von Hui Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Therapy, Ningbo NO.2 Hospital, Ningbo, Zhejiang, People's Republic of China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Therapy, Ningbo NO.2 Hospital, Ningbo, Zhejiang, People's Republic of China.
ORCID-Profile: Hui Yang, Tiequan Yang, Guangpin Qiu, Jie Liu
Zitieren
APA
Yang, H., Yang, T., Qiu, G., & Liu, J. (2023). Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study. Journal of Hepatocellular Carcinoma, Volume 10, 1435-1443. https://doi.org/10.2147/jhc.s423684
Vancouver
Yang H, Yang T, Qiu G, Liu J. Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study. Journal of Hepatocellular Carcinoma. 2023;Volume 10:1435-1443. doi:10.2147/jhc.s423684
BibTeX
@article{Yang2023,
author = {Yang, Hui and Yang, Tiequan and Qiu, Guangpin and Liu, Jie},
title = {Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study},
journal = {Journal of Hepatocellular Carcinoma},
year = {2023},
volume = {Volume 10},
pages = {1435--1443},
doi = {10.2147/jhc.s423684}
}
EUVIMED